Drug intelligence / Profile preview

ALID-10

Development stage: Unknown
Lead developer: Allied Biotech

Overview

ALID-10 is an investigational pharmaceutical drug candidate being developed by Allied Corp for the treatment of post-traumatic stress disorder. Based on the provided source context, it is in Phase I clinical development. No specific active ingredient, molecular identity, modality beyond being a pharmaceutical product, formulation details, route of administration, or validated biological mechanism of action were disclosed in the supplied materials, so its pharmacology remains unspecified from the available evidence.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on ALID-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALID-10.

Explore the full profile